Rybrevant (amivantamab-vmjw)
Janssen Oncology (Johnson & Johnson) · Bispecific Antibody — EGFR × MET
What is Rybrevant? Rybrevant (amivantamab-vmjw) is a bispecific antibody targeting EGFR and MET by Janssen. It is FDA-approved for NSCLC with EGFR exon 20 insertion mutations, and in combination with lazertinib for EGFR-mutant NSCLC after osimertinib and platinum chemotherapy.
About Rybrevant
| Brand Name | Rybrevant |
| Generic / INN | amivantamab-vmjw |
| Drug Class | Bispecific Antibody — EGFR × MET |
| Manufacturer | Janssen Oncology (Johnson & Johnson) |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2021 |
FDA-Approved Uses for Rybrevant
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations — after platinum-based chemotherapy
- Locally advanced or metastatic EGFR-mutated NSCLC — in combination with lazertinib (Lazcluze) after failure of osimertinib and platinum-based chemotherapy
- Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations — first-line, in combination with lazertinib
How Does Rybrevant Work?
Amivantamab-vmjw simultaneously targets EGFR and MET receptors on tumor cells. It blocks ligand binding, promotes EGFR and MET receptor degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis — directly killing tumor cells through immune effector mechanisms in addition to receptor blockade.
Dosage & Administration
Weight-based dosing: 1050 mg IV (body weight <80 kg) or 1400 mg IV (body weight ≥80 kg). First infusion over 5 hours; subsequent infusions over 3 hours if previous infusion well tolerated. Premedication required to reduce infusion-related reactions.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
Infusion-related reactions — premedication required; split first dose over 2 days for high-risk patients. Interstitial lung disease / pneumonitis. Dermatologic toxicity (rash, paronychia) — very common. Ocular toxicity. Venous and arterial thromboembolism. Embryo-fetal toxicity.
- Infusion-related reactions
- Interstitial lung disease / pneumonitis
- Dermatologic toxicity
- Ocular toxicity
- Venous thromboembolism
- Embryo-fetal toxicity
Common Side Effects
- Rash (acneiform / dermatitis)
- Infusion-related reactions
- Paronychia
- Fatigue
- Nausea
- Edema
- Peripheral neuropathy
- Decreased appetite
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Rybrevant is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Rybrevant. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Rybrevant
Rybrevant (amivantamab-vmjw) is a bispecific EGFR×MET antibody by Janssen approved for NSCLC with EGFR exon 20 insertion mutations and in combination with lazertinib for other EGFR-mutant NSCLC settings.
EGFR exon 20 insertions are a specific type of EGFR mutation in non-small cell lung cancer that is generally resistant to first and second-generation EGFR inhibitors (gefitinib, erlotinib, afatinib) and even osimertinib. Rybrevant was the first FDA-approved therapy specifically for this mutation.
Dermatologic toxicity (acneiform rash, paronychia — nail inflammation) is very common with amivantamab. Proactive skin management with topical antibiotics and moisturizers is recommended.
Rybrevant is covered by Medicare Part B and commercial insurance for approved EGFR-mutant NSCLC indications with biomarker documentation and prior authorization. BiologicHealthPlus manages the full PA process.
Related Medications & Conditions
Related Medications
Lazcluze (lazertinib) · Tagrisso (osimertinib) · Keytruda (pembrolizumab) · Bizengri (zenocutuzumab)
Related Conditions
EGFR exon 20 insertion NSCLC · EGFR-mutant NSCLC · Non-small cell lung cancer